Breye Therapeutics appoints Gabriela Burian to its Board of Directors and announces Dr. Peter Adamson as CSO

– DENMARK, Copenhagen – Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announced the appointments of Gabriela Burian to its Board of Directors and of Dr. Peter Adamson as CSO.

About Gabriela Burian

Gabriela Burian is a physician-scientist with over 25 years of experience in clinical research and drug development in ophthalmology. She has held various global leadership positions at leading biopharmaceutical companies including Roche and Novartis.

About Dr. Peter Adamson

Dr. Peter Adamson has over 20 years of experience in ophthalmology drug development. He has previously held senior leadership positions at various biopharmaceutical companies including VP and Head of Ophthalmology Research at GlaxoSmithKline, where he generated multiple clinical candidates and acted as Lead Biologist on several discovery programs. He previously also worked at ProQR and recently Tenpoint Therapeutics, where he built pipelines and secured successful financing.

About Breye Therapeutics

Breye is a biopharmaceutical company developing novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to Diabetic Retinopathy (DR) or Age-Related Macular Degeneration, for which there are no treatments in early or moderate disease. Danegaptide is an oral investigational compound that targets diabetic retinopathy, a serious complication of a rapidly growing global disease. Severe diabetic retinopathy requires intravitreal injections directly into the eye, which are unpopular with patients, resulting in a significant dropout rate of about 50% after 1 year and only 40% of patients obtain an optimal response. Initially developed for cardiac indications, clinical studies have shown danegaptide to be a safe drug, stabilizing cell-cell coupling and protecting against vascular leakage and capillary breakdown. Danegaptide is orally administered and less burdensome than injections, as well as potentially more effective and commercially competitive. With its recognized safety profile, danegaptide has the potential for a short and well-accepted clinical regulatory pathway. Breye is also developing an oral P2X7R inhibitor for AMD which seeks to reduce nerve damage and inflammation.

Breye raised a seed round from Novo Holdings and Sound BioVentures and received financial support from the BioInnovation Institute, the Danish Growth Foundation (Vækstfonden), and the Danish Innovation Foundation (Innovationsfonden).


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.